InvestorsHub Logo
Followers 62
Posts 1712
Boards Moderated 0
Alias Born 08/08/2005

Re: None

Wednesday, 02/09/2011 6:01:58 PM

Wednesday, February 09, 2011 6:01:58 PM

Post# of 346046
Peregrine’s multiple clinical trials and IST’s are advancing and maturing with a primary goal of achieving an initial FDA approval for bavituximab in oncology.

Company policies and objectives recognize the underlying value of the technological platforms and the potential value of the drug pipeline. The value of even just treating the solid tumor cancers with bavituximab will be immense. Peregrine holds the potential worldwide market for bavituximab: anti-cancer and anti-viral.

Recent monthly PPHM trade volume has markedly increased and remains strong. It appears that quite large new positions in Peregrine have begun to be reported. These seem to be solid markers. Price follows volume.

GLTA this year.

sunstar
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News